STOCK TITAN

Nuvation Bio (NUVB) CSO sells 100K shares at $7.09

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nuvation Bio Inc. (NUVB) reported that Chief Scientific Officer Gary Hattersley exercised options for 100,000 shares of Class A Common Stock at an exercise price of $1.87 per share and sold 100,000 shares on the same date at a weighted-average price of $7.0924, under a Rule 10b5-1 trading plan dated December 4, 2025. Following the option exercise, he held 400,000 stock options directly, with the option expiring on February 27, 2034 and vesting 25% after one year from February 29, 2024 and monthly over the next 36 months, subject to continued service.

Positive

  • None.

Negative

  • None.
Insider Hattersley Gary
Role CHIEF SCIENTIFIC OFFICER
Sold 100,000 shs ($709K)
Approx. gross sale proceeds $709K
Approx. exercise cost $187K
Approx. pre-tax spread $522K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F3 100,000 $0.00 $0.00
Exercise Class A Common Stock 100,000 $1.87 $187K
Sale Class A Common Stock F1, F2 100,000 $7.0924 $709K
Holdings After Transaction: Stock Option (Right to Buy) — 400,000 shares (Direct); Class A Common Stock — 0 shares (Direct)
Footnotes (3)
  1. F1. Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
  2. F2. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.02 to $7.21. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  3. F3. Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
Shares sold 100,000 shares Class A Common Stock sold on August 19, 2026
Weighted-average sale price $7.0924 per share Sales of 100,000 shares on August 19, 2026; prices ranged $7.02–$7.21
Option exercise size 100,000 shares Stock Option (Right to Buy) exercised into Class A Common Stock
Option exercise price $1.87 per share Conversion or exercise price for 100,000 underlying shares
Options held after transaction 400,000 stock options Total Stock Option (Right to Buy) shares following the exercise
Option expiration date February 27, 2034 Expiration date of the exercised stock option grant
10b5-1 plan date December 4, 2025 Date of Rule 10b5-1 trading plan governing the share sale
Rule 10b5-1 plan regulatory
"Shares sold pursuant to a 10b5-1 plan dated December 4, 2025."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Stock Option (Right to Buy financial
"security_title: "Stock Option (Right to Buy)""
weighted-average sales price financial
"Price reported is a weighted-average sales price."
Class A Common Stock financial
"underlying_security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
continuous service other
"subject to Reporting Person's continuous service on each such vesting date."

FAQ

What insider transactions did NUVB Chief Scientific Officer Gary Hattersley report?

Gary Hattersley exercised options for 100,000 shares of NUVB Class A Common Stock at $1.87 per share and sold 100,000 shares on the same date at a weighted-average price of $7.0924, in a sequence of option exercise followed by share sale.

Were the recent NUVB insider share sales made under a Rule 10b5-1 plan?

Yes. The filing states that shares were sold pursuant to a Rule 10b5-1 plan dated December 4, 2025. The document-level Rule 10b5-1 checkbox is also affirmed, indicating the reported transactions occurred under a pre-arranged trading plan.

At what prices did the NUVB insider sell shares on August 19, 2026?

The reported weighted-average sales price was $7.0924 per share. A footnote explains that the actual sale prices ranged from $7.02 to $7.21 per share, and the reporting person will provide detailed breakdowns of shares sold at each separate price upon request.

What is the size and strike price of the NUVB stock option exercised by the CSO?

The CSO exercised a stock option for 100,000 underlying shares of Class A Common Stock at an exercise price of $1.87 per share. After this transaction, the filing shows 400,000 stock options held directly following the transaction.

When does the NUVB stock option held by the CSO expire and how does it vest?

The stock option expires on February 27, 2034. A footnote states it vests 25% on the one-year anniversary of February 29, 2024, with the remainder vesting monthly over the following 36 months, subject to the CSO’s continuous service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hattersley Gary

(Last)(First)(Middle)
C/O NUVATION BIO INC.
1500 BROADWAY, SUITE 1401

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF SCIENTIFIC OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock08/19/2026M100,000A$1.87100,000D
Class A Common Stock08/19/2026S(1)100,000D$7.0924(2)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.8708/19/2026M100,000 (3)02/27/2034Class A Common Stock100,000$0400,000D
Explanation of Responses:
1. Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
2. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.02 to $7.21. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
3. Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
/s/ Stephen Dang, Attorney-in-Fact08/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)